Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Overview of attention for article published in New England Journal of Medicine, September 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 53 news outlets
blogs: 12 blogs
policy: 2 policy sources
twitter: 239 X users
patent: 41 patents

facebook: 4 Facebook pages
wikipedia: 2 Wikipedia pages
googleplus: 1 Google+ user
f1000: 1 research highlight platform

Citations

dimensions_citation: 4898 Dimensions

Readers on

mendeley: 2064 Mendeley
citeulike: 1 CiteULike

Summary News Blogs Policy documents X Patents Facebook Wikipedia Google+ Research highlights Dimensions citations

So far, Dimensions has found 4,898 publications that cite this research output.

4,898

The most recent citing publications are shown below. View all 4,898 publications that cite this research output on Dimensions.

Molecular uropathology: what a practising pathologist should know

Article in Diagnostic Histopathology (May 2024)

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

Article in Future Oncology (April 2024)

Real‐world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients

Article in Asia-Pacific Journal of Clinical Oncology (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.